2015 American Transplant Congress
Incidence and Risk Factors for Infectious Complications in Liver Transplant Patients Converted to Everolimus
AIM:Immunosuppression with an mTOR inhibitor plus calcineurin inhibitor (CNI) minimization is increasingly used in liver transplantation to protect against the nephrotoxic and neurotoxic side effects…2015 American Transplant Congress
Current Status of US Intestinal and Multivisceral Transplantation: An Analysis of the UNOS Intestine Transplant Registry
The purpose of this study is to analyze the current status of US intestinal transplantation (IT). As of 9/19/2014, 2441 IT have been performed in…2015 American Transplant Congress
Conversion to Belatacept After Kidney Transplantation Does Not Alter Immunophenotype
1University Medicine Charité, Berlin, Germany; 2Labor Berlin GmbH, Berlin, Germany.
Belatacept offers a new option for renal allograft recipients who are suffering from side effects of calcineurin inhibitor or mTOR. Such a conversion may result…2015 American Transplant Congress
Immune Phenotyping of Peripheral Blood Samples from the CTOT-10 Belatacept Study
The purpose of the CTOT-10 study is to evaluate belatacept as maintenance therapy, while minimizing calcineurin inhibitors and corticosteroids in renal transplantation. We designed mechanistic…2015 American Transplant Congress
Safety and Efficacy of Conversion from Conventional Twice Daily Tacrolimus to Once Daily Extended Release Tacrolimus in Stable Pancreas Transplant (SPK and PAK) Recipients
Surgery, Multi-Organ Transplant, Toronto General Hospital, Toronto, ON, Canada.
Background: A once-daily, modified-release oral formulation of tacrolimus has been developed to simplify dosing and improve medication adherence. There is limited data on the implementation…2015 American Transplant Congress
Pyridoxine Deficiency After Solid Organ Transplant
BackgroundMicronutrient deficiencies have been discussed in the literature regarding post-transplant recipients. A proposed theory is that immunosuppressive medications or altered immune system cause pyridoxine deficiency…2015 American Transplant Congress
Pharmacokinetics of Everolimus (EVL) in Elderly Recipients Under Low-Tacrolimus(TAC)/Everolimus in the First Year After Renal Transplantation. Data from the NEverOLd Trial
Elderly ( >60 years) recipients are being renal transplanted more frequently. The pharmacokinetics studies (PK) of immunosuppressive drugs in healthy volunteers, rarely, if ever, include…2015 American Transplant Congress
Mycophenolate Dose Reductions Contribute to Suboptimal Graft Outcomes in Kidney Transplant Recipients
Medical University of South Carolina, Charleston, SC.
The purpose of this study was to analyze outcomes in patients with mycophenolate mofetil (MMF) dose reductions below doses proven to prevent rejection in a…2015 American Transplant Congress
In Vivo Expansion of Donor-Specific Regulatory T Cells by a New Triazolopyrimidine Derivative and Donor-Specific Transfusion
Background: We have previously demonstrated that a new triazolopyrimidine derivative, NK026680 (NK) prevents activation/maturation of dendritic cells. This study investigated whether NK together with donor-specific…2015 American Transplant Congress
TIM-4 Identifies IL-17 Expressing Pro-Inflammatory Be-17 Cells That Promote Allograft Rejection
Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.
We identified TIM-1 as an inclusive marker for IL-10+ regulatory B cells (TIM-1+ Bregs), which prolong islet allograft survival (GS). We recently found that TIM-4,…
- « Previous Page
- 1
- …
- 119
- 120
- 121
- 122
- 123
- …
- 138
- Next Page »